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Objectives. The purpose of this review is to summarize literature pertaining to clinical roles of positron emis-
sion tomography (PET) or integrated PET and computed tomography (PET/CT) scans, magnetic resonance imag-
ing (MRI) and emerging techniques of these two molecular imaging tools for gynecologic malignancies.
Methods. PubMed and MEDLINE databases search for articles published before June 2014 was performed.
Only English-language articles were considered. Search terms included “cervical cancer”, “endometrial cancer”,
“uterine cancer”, “uterine sarcoma”, “ovarian cancer” and “vulvar cancer”, in association with “FDG”, “PET”,
“PET/CT”, “MRI”, “PET/MR”, “diffusion”, “spectroscopy” and “clinical trial”.
Results. Topics explored included PET, PET/CT and MRI for diagnosis of malignancy, prognostic implications,
clinical staging of disease extent, monitoring treatment response, post-therapy surveillance, diagnosis of treat-
ment failure and restaging, and follow-up after salvage therapy in gynecologic malignancies.
Conclusions.Molecular imaging (mainly PET and MRI) plays important roles in the management of gyneco-
logic malignancies. Molecular imaging has various impacts in different clinical scenarios. Emerging technologies
will continuously improve our practice. Prospective studies with deﬁned endpoints are necessary to evaluate
roles of these novel tools in management of gynecologic malignancies.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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Table 2
The possibility of imaging parameters to predict surgical–pathological ﬁndings listed on
FIGO staging/AJCC 2010 7th edition.
MRI PET/CT PET/MR*
Cervical carcinoma
Early detection Y Y Y
Differential diagnosis Y N Y
Staging
Size (more than or less than 4.0 cm) Y N Y
Vaginal invasion C N Y
Parametrial invasion C N Y
Pelvic wall invasion Y Y Y
Invasion to lower third of vagina Y N Y
Invasion to bladder mucosa U N N
Invasion to rectum mucosa Y N Y
Extends beyond true pelvis Y Y Y
Regional pelvic lymph node metastasis C C Y
Distant metastasis para-aortic lymph nodes C C Y
Distant metastasis (including peritoneal spread,
involvement of supraclavicular, mediastinal,
or lung, liver, or bone)
Y Y Y
Prognosis Y Y Y
Response evaluation Y Y Y
Surveillance Y Y Y
Management of recurrence Y Y Y
Endometrial carcinoma
Early detection Y Y Y
Differential diagnosis Y N Y
Staging
Limited to endometrium or invades less than
one-half or one-half or more of the myometrium
Y N Y
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Molecular imaging is a means of in vivo visualization of the key mo-
lecularly based events, which represents the cancer phenotype and has
potential as imaging biomarkers [1] applied in cancer management [2].
Magnetic resonance imaging (MRI) has advanced toward scale beyond
the anatomical structures in many aspects. Diffusion-weighted imaging
(DWI) measures Brownian motion of molecules and highlights the in-
creased cellularity of cancer tissue, which can be quantitatively evaluated
on the apparent diffusion coefﬁcient (ADC) map [3]. Dynamic contrast
enhancement (DCE)-MRI makes use of intravenous gadolinium-based
contrast agent that is blocked by the tight-junction of the normal blood
vessel but leaks out through the neovascularization in the tumor, which
provide profuse modeling information such as blood ﬂow, extraction
fraction, blood volume, volume of extravascular extracellular space
(ESS), capillary permeability surface area product and transfer from
blood to EES (Ktrans) [4]. MR spectroscopy (MRS) is a technique that
can semi-quantitatively acquire chemical composition in a selected region
of interest [5]. Nowadays most clinical MR scanners have routine se-
quences for proton (1H)-MRS measurements, providing a range of meta-
bolic and functional information integrated with complementary MRI
localization. Positron emission tomography (PET), on the other hand,
can provide functional or metabolic information with speciﬁcally labeled
radiotracers suitable for different disease scenarios [6]. Integrated PET and
computed tomography (PET/CT) scan using 18F-ﬂuorodeoxyglucose
(FDG) is now widely used clinically, and many potential radiotracers
other than FDG are under development (Table 1). In addition to radio-
tracers development, imaging parameter breakthrough has translated
the semi-quantitative information of tumor to our daily practice, e.g. stan-
dardized uptake valuemaximum (SUVmax), total lesion glycolysis (TLG),
metabolic tumor volume (MTV). Texture feature technology has been de-
veloped in PET recently and showed improvement in describing
intratumoral heterogeneity and tumor landscape in certain cancers [7].
Through the strength of low radiation dose and high soft tissue contrast,
the introduction of hybrid PET/MRI may possibly bring molecular image
in clinical application to a new era [8].Table 1
PET radiotracers for evaluation of biologic processes in oncology.





11C-cholinea Choline kinase activity/synthesis
of membrane phospholipids
18F-ﬂuorocholine Choline kinase activity/synthesis
of membrane phospholipids
11C-methionine Amino acid metabolism
O-(2-18F-ﬂuoroethyl)-L-tyrosine Amino acid metabolism










11C-acetate Fatty acid metabolism
11C-palmitate Fatty acid metabolism
Nitrogen-13 ammoniaa Blood ﬂow
Oxygen-15 water Blood ﬂow
Rubidium-82 chloridea Blood ﬂow
18F-sodium ﬂuoride (18F-NaF)a Bone metabolism/calciﬁcation
16a-18F-ﬂuoroestradiol-17b Estrogen receptors
Note: Radiotracers listed are a small selection of the many available.
a US Food and Drug Administration-approved radiotracers.The purpose of this review is to summarize literature pertaining to
clinical roles of MRI and PET for gynecologic malignancies (Table 2)
and emerging techniques of these two major molecular imaging tools.
Diagnosis of malignancy
Molecular imaging may predict the degree of malignancy in ovary
tumors or uterine sarcoma sparing endometrium. This function inUterine serosa invasion Y U Y
Invasion to stromal connective tissue of the cervix N N Y
Adnexal direct extension or metastasis U U Y
Vaginal involvement (direct extension or metastasis) Y N Y
Parametrial involvement U U Y
Invasion to bladder mucosa U N N
Invasion to bowel mucosa Y N Y
Regional pelvic lymph node metastasis C C Y
Regional para-aortic lymph node metastasis C C Y
Distant metastasis (includes metastasis to inguinal
lymph nodes, intra-peritoneal disease, or lung,
liver, or bone. It excludes metastasis to para-aortic
lymph nodes, vagina, pelvic serosa, or adnexa)
Y Y Y
Prognosis Y Y Y
Response evaluation Y Y Y
Surveillance Y Y Y
Management of recurrence Y Y Y
Ovarian cancer
Early detection C C Y
Differential diagnosis Y N Y
Staging
Tumor limited to one or both ovary U U Y
Ovarian capsule intact or ruptured N N N
Tumor on ovarian surface Y Y Y
Malignant cells in ascites or peritoneal washing N N N
Extension and/or implants on uterus and/or tube(s) Y Y Y
Peritoneal metastasis beyond pelvis more than
2 cm in greatest dimension
Y Y Y
Regional lymph node metastasis U U Y
Distant metastasis (excludes peritoneal metastasis) Y Y Y
Prognosis Y Y Y
Response evaluation Y Y Y
Surveillance Y Y Y
Management of recurrence Y Y Y
Y = yes. N = no. U = unknown. C = controversy. *, based on prediction.
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because tissue diagnosis is often made before surgical intervention.
Risum et al. showed that FDG-PET/CT is superior to CT or conventional
MRI, in distinguishing malignant or borderline tumor from benign
ovarian tumors, yielding a sensitivity of 92–100% and a speciﬁcity of
85–92.5% in identifying primary ovarian cancer in patients with a pelvic
mass and risk of malignancy index (RMI) N 150 [9]. In a recent prelimi-
nary report the choline peak on MR spectra was detected in malignant
ovarian tumors and was absent in apparently healthy pelvic tissues,
which opens new researchwindow for early diagnosis of ovarian cancer
[10].
In preoperative diagnosis of uterine leiomyosarcoma, Tanaka et al.
demonstrated the presence of high signal on T2-weighted image, any
small high-signal areas on T1-weighted image, or areas of unenhanced
pocket as imaging features suggestive of leiomyosarcoma or smooth
muscle tumors of uncertain malignant potential (n = 12) [11]. Sato
et al. reported a combination of signal intensity on DWI and ADC
value on MRI, yielding a sensitivity of 100% and a speciﬁcity of 94% in
imaging diagnosis of leiomyosarcoma (n = 5) [12]. More recently,





PET outperforms FDG-PET (p b 0.01) in differentiation of SUVmax
between malignant uterine corpus tumors (n = 5) from benign
leiomyoma (n = 10) [13]. To date no adequate evidence has been pro-
vided by a large scale or prospective study partly because of rareness of
uterine sarcoma. In cervical cancer, radiotracers other than FDG such as
64Cu-labeled diacetylbis(N4-methylthiosemicarbazone) (64Cu-ATSM)
were used to demonstrate hypoxia and 11C-choline for proliferative
activity, yet have not gained popularity [14].
Clinical staging of disease extent
Precise clinical staging is crucial for selection of primary therapy for
cervical cancer. Generally, International Federation of Gynecology and
Obstetrics [FIGO] stages IA1–IIA1 diseases can be treatedwith either pri-
mary surgery or radiotherapy (RT), while stages IB2 to IV (except IIA1)
diseases can be treated with deﬁnitive radiation with concurrent
platinum-based chemotherapy [14]. MRI was found useful to conﬁrm
the absence of residual tumor in the cervix after a cone biopsy with
negative margins in selection of patients for fertility-sparing radical
trachelectomy [15]. Results of the intergroup study American College
of Radiology Imaging Network (ACRIN) 6651/Gynecologic Oncology
Group (GOG) 183 showed that, in patients with early-stage cervical
cancer scheduled for curative radical hysterectomy, MRI is superior to
CT by receiver operating curve (ROC) analysis (area under the curve
[AUC] 0.80 vs. 0.66, respectively; p b 0.01), for evaluating uterine body
involvement and measuring tumor size [16], and has a sensitivity of
53% and a speciﬁcity of 74% in detection of parametrial invasion
(≥ IIB) [17]. A European multicenter trial to evaluate tumor delineation
by MRI in early-stage cervical cancer showed that, the agreement
between MRI and histology was good for classifying tumors as b2 cm,
or N4 cm, and detecting deep stromal invasion (kappa values of 0.77,
0.76, 0.77, respectively), but only moderately accurate in assessing
parametrial invasion (kappa values of 0.52, 0.45, respectively) [18].
Data from the ACRIN 6651/GOG 183 study showed MRI has only a
sensitivity of 37% but a speciﬁcity of 94% in detecting pelvic lymph
node (LN) metastases [19]. Lin et al. has demonstrated a combination
of size and relative ADC values on DWI being useful in detecting pelvic
LN (PLN)metastasis in patients' populationmixedwith cervical and en-
dometrial cancer, trying to provide a better sensitivity (25% vs. 83%) and
maintain a similar speciﬁcity (98% vs. 99%), as compared with conven-
tional MRI [20]. Chou et al. [21] showed that FDG-PET detected only
one of the 10 MRI-negative pelvic metastatic LNs in patients with pri-
mary, non-bulky, stages IA2 to IIA cervical cancer. The PET false-
negative PLN containing micro-metastasis measured a short axis diam-
eter of only 0.5–6mm [21]. Kitajima et al. compared DWI and FDG-PET/
CT in evaluation of LN metastasis in cervical and endometrial cancer,showing that DWI has a higher sensitivity (83.3% vs. 38.9%) but a
lower speciﬁcity (51.2% vs. 96.3%) than FDG-PET/CT [22]. Kim et al. eval-
uated the additional diagnostic value of FDG-PET and MRI fusion in the
detection ofmetastatic LNs in cervical cancer patients, with the sensitiv-
ity and speciﬁcity of FDG-PET/CT and fused FDG-PET/MR being 44.1%,
93.9% and 54.2%, 92.7% respectively [23].
Detection of paraaortic LN (PALN) metastasis is an important issue
because extended-ﬁeld RT is indicated based on PALN positivity, al-
though it remains controversial whether extraperitoneal paraaortic
lymphadenectomy should be performed [24]. In patients having nega-
tive ﬁndings of PALN on CT or MRI, the sensitivity and speciﬁcity of
FDG-PET/CT were 33–36% and 94–96%, respectively, using laparoscopic
paraaortic lymphadenectomy histology as a gold standard [25,26]. In
patients with stage IB/IIB cervical adenocarcinoma or adenosquamous
carcinoma, the diagnostic efﬁcacy in identifying metastatic PALN was
signiﬁcantly higher in FDG-PET than in MRI, with a sensitivity of 66.7%
and a speciﬁcity of 100%, based on surgical histopathology [27]. Tsai
et al. demonstrated that pretreatment FDG-PET improves the detection
of extrapelvic metastasis on MRI, mainly PALN, and helps to select pa-
tients for extended-ﬁeld RT, albeit not translating into survival beneﬁt,
even with a reduced rate in PALN relapse [28].
For patients who present with distant metastatic disease (i.e., stage
IVB), primary treatment is often cisplatin-based chemotherapy. In
these situations, individualized RTmay be considered for control of pel-
vic disease and other symptoms. For newly diagnosed cervical cancer
FIGO stage ≥ IB, FDG-PET/CT has a sensitivity of 100% and a speciﬁcity
of 94% in detecting distant metastases [29]. Liu et al. demonstrated the
superiority of FDG-PET over CT and MRI for detecting hematogenous
bone metastasis in FIGO stage III/IV or positive LN metastasis cervical
cancer patients upon primary staging [30]. However, FDG-PET/CT
should be interpreted cautiously for isolated mediastinal involvement
in newly diagnosed cervical cancer patients, because 75% of themedias-
tinal LNs with increased FDG uptake were eventually conﬁrmed histo-
pathologically to be granulomatous changes only and free of tumor [31].
For endometrial cancer, Antonsen et al. reported a Danishmulticenter
prospective comparative study showing the prediction of myometrial in-
vasion, the sensitivity and speciﬁcity being 93% and 49% for FDG-PET/CT,
and 87% and 57% for conventionalMRI [32]. Lin et al. demonstrated fused
T2-weighted and high-b-value DWI at 3T can provide accurate informa-
tion for preoperative evaluationofmyometrial invasion,with a sensitivity
of 86% and a speciﬁcity of 100% [33]. Regarding the detection of cervical
invasion, the sensitivity of both FDG-PET/CT and MRI was suboptimal
(43% and 33%, respectively) [32].
For preoperative diagnosis of LN metastases in patients with endo-
metrial carcinoma, the sensitivity and speciﬁcity of FDG-PET/CT were
67–74% and 93–94% respectively, superior to those of MRI, 59% and
93%, proven by surgical staging [32,34]. Suzuki et al. reported that
FDG-PET had a sensitivity superior to CT/MRI, in detection of extrauter-
ine lesions excluding retroperitoneal LNs (83.3% vs. 66.7%), although
there was no difference in the speciﬁcity among the modalities (100%)
[35]. FDG-PET also had a higher speciﬁcity (100%) compared with CT/
MRI (85.7%), but still could not detect LN metastatic lesions smaller
than 0.6 cm in short-axis diameter [35]. Ho et al. [36] showed that
FDG-PET is beneﬁcial in excluding falsely inoperable carcinosarcoma
for curative therapy and in making a decision on palliation for better
quality of life instead of aggressive treatment.
Regarding ovarian cancer, Hynninen et al. showed a substantial
number of patients with advanced ovarian cancer stages IIC–IV
showing supra-diaphragmatic nodal metastasis in pre-treatment
FDG-PET/CT, suggesting that the route of ovarian cancer cells from
the peritoneal cavity to the lymphatic system permeates the dia-
phragm mainly to the cardiophrenic node and continues to the
parasternal LNs [37]. A meta-analysis demonstrated that, FDG-PET
or FDG-PET/CT (sensitivity, 73.2%; speciﬁcity, 96.7%) is more accu-
rate than CT (sensitivity, 42.6%; speciﬁcity, 95.0%) or MRI (sensitivi-
ty, 54.7%; speciﬁcity, 88.3%) in the detection of LN metastasis in
159C.-H. Lai et al. / Gynecologic Oncology 135 (2014) 156–162patients with ovarian cancer [38], while Michielsen et al. found that
whole body MRI with DWI has a higher accuracy (91%) as compared
with CT (75%) or FDG-PET/CT (71%) for peritoneal staging [39]. This
is in line with our experience showing an additional DWI that
could improve the performance of MRI, but reader experience still
plays crucial roles in imaging interpretation.
Kataoka et al. reported that MRI has an accuracy of 85% in staging
of primary vulvar cancers, and 87% in the prediction of groin nodal me-
tastasis [40]. Cohn et al. showed that FDG-PET is relatively insensitive,
with a sensitivity of 67% and a speciﬁcity of 95%, in predicting groin
nodal metastasis, whereas FDG-PET is more accurate for detecting
extranodal metastases than the disease conﬁned within the groin
nodes (p = 0.048) [41].
Prognostic implications
In addition to anatomical details, molecular imaging also provides
quantitative information as prognostic indicators. Kidd and Grigsby
showed that in FIGO stages IB1 to IVA cervical cancer treated with che-
moradiation, intratumoral FDG metabolic heterogeneity on the pre-
treatment FDG-PET predicted the risks of LN involvement at disease
diagnosis, response to therapy and pelvic recurrence [42]. Crivellaro
et al. showed that in patients with cervical cancer FIGO stages IB1 and
IIA with tumor less than 4 cm, MTV and TLG of cervical lesions on
FDG-PET/CT predict nodal metastases but does not predict recurrence
[43]. Yen et al. showed that a SUVmax ≥ 3.3 for PALN and FIGO stage
≥ III were adverse factors for patients with primary squamous cervical
carcinoma with PLN or PALN metastasis detected by CT/MRI [44].
Results from Ho et al. justiﬁed the use of FDG-PET (accurate extent of
relapse and SUV) as a prognostic tool in cervical cancer patients with
supraclavicular LN recurrence, showing that SUV of b4.3 or N8 were
signiﬁcant adverse prognostic factors by multivariate analysis [45].
Antonsen et al. found that preoperative SUVmax of endometrial
tumor is signiﬁcantly higher in patients with high FIGO stages,
deep myometrial invasion, cervical invasion, LN metastasis and
high-risk tumors. However, the sensitivity and speciﬁcity of the
SUVmax in staging endometrial cancer is not high enough to reliably
replace surgical staging [46]. The preoperative SUVmax is also supe-
rior to ADCmin of the primary tumor as a predictor of disease recur-
rence and survival in patients with endometrial cancer [47]. Liu et al.
reported that MTV by FDG-PET/CT is prognostic for stage IVB endo-
metrial carcinoma [48], with 4 patients with total body MTV above
450 mL (or total body TLG above 2700 g) having a median survival
of 2 months, while the remaining patients having a median survival
of 47 months.
Response evaluation, surveillance, and themanagementof recurrence
Imaging is indicated in patients with symptoms or ﬁndings
that are suspicious for recurrence but not routinely recommended
for surveillance [49]. According to the NCCN Guidelines, in patients
at high risk for locoregional failure, a combined PET/CT scan
(e.g., 3–6 months after treatment) or other radiologic imaging may
be useful for detecting asymptomatic disease that is potentially cur-
able [49]. deSouza et al. assessed tumor response to neoadjuvant
chemotherapy prior to radical hysterectomy in FIGO stages IB–IIB
previously untreated cervical tumors N10 cm3, and found a signiﬁ-
cant reduction in tumor volume onMRI and\CH2 triglyceride levels
on MRS after neoadjuvant chemotherapy [50]. Furthermore, Harry
et al. showed that ADC values was reproducible and showed a signif-
icant correlation with eventual clinical response, hence has potential
to provide a surrogate biomarker of treatment response in advanced
cervical cancers [51].
In patients with cervical cancer who experienced complete re-
sponses to primary treatment or salvage therapy, there is no evidence
of recurrent disease as detected by conventional CT or MRI, but hadserum squamous cell carcinoma antigen (SCC-Ag) level elevation on
two consecutive occasions. Chang et al. demonstrated that FDG-PET ex-
pedited the detection (94%) of recurrence [52]. Chung et al. reported
that the overall sensitivity and speciﬁcity of post-treatment FDG-PET/
CT were 94.7% and 87.8% [53]. Yen et al. deﬁned the priority of using
FDG-PET in cervical cancer patients after a deﬁnitive treatment with
documented failure or unexplained elevated tumor marker in serum.
Primary radiation treatment, SCC-Ag ≥ 4 ng/mL, and the presence of
symptoms at recurrence were signiﬁcant factors of poor survival. FDG-
PET may offer maximal beneﬁts by selecting appropriate recurrent
cervical cancer patients for salvage therapywith precise restaging infor-
mation [54]. In patients with cervical carcinoma who experienced con-
ﬁrmed treatment failure but who were feasible candidates for curative
salvage therapy, FDG-PET was signiﬁcantly superior to CT/MRI (sensi-
tivity: 92% vs. 60%) in identifying metastatic lesions, and led to treat-
ment plan modiﬁcations in 55% of the participants [55]. The beneﬁts
of FDG-PET exceed those of CT-MRI mainly because of the ability of
FDG-PET to identify extra-pelvic metastases and its higher sensitivity
and speciﬁcity [56]. Overall FDG-PET has a positive impact on 46%
patients in cervical cancer patients with histologically documented re-
recurrence after curative salvage therapy or unexplained tumor marker
elevation [57].
Park et al. evaluated the clinical impact of FDG-PET or FDG-PET/
CT in the post-therapy surveillance of endometrial carcinoma. In pa-
tients with suspected disease recurrence, the sensitivity and speci-
ﬁcity of FDG-PET and/or FDG-PET/CT in detecting recurrence in
these patients were 100% and 83.3%, respectively. In asymptomatic
patients for routine post-therapy surveillance, the sensitivity and
speciﬁcity of FDG-PET or FDG-PET/CT were both 100%. FDG-PET
and/or FDG-PET/CT were highly effective in discriminating true re-
currence in patients with suspected recurrence, highly sensitive in
detecting recurrence in asymptomatic patients, and had impacts on
clinical decisions in a considerable portion of patients [58]. Chao et al.
reported that, in primary advanced (stage III/IV), or suspicious/docu-
mented recurrent endometrial cancer or surveillance after salvage thera-
py, FDG-PET plus MRI or CT was signiﬁcantly superior to MRI or CT alone
in overall lesion detection, detection of pelvic nodal/soft tissue metasta-
ses and detection of extrapelvic metastases (AUC 0.949 vs. 0.872; p =
0.004). Positive clinical impactwasmore often seen among those for sus-
picious/documented recurrence or post-salvage surveillance (70%) than
primary staging (22.2%) [59]. Sironi et al. examined the value of integrat-
ed FDG-PET/CT in the detection of recurrence in postsurgical surveillance
of patients with cervical or endometrial cancer with suspicion of recur-
rence based on the results of routine follow-up procedures, demonstrat-
ing a patient-based sensitivity and speciﬁcity of FDG-PET/CT for the
detection of tumor recurrence were 92.9% and 100.0% [60]. Ho et al.
[36] reported that FDG-PET has a limited value in post-therapy surveil-
lance or restaging after failure for uterine carcinosarcoma. In another se-
ries comprising patients with uterine leiomyosarcoma, carcinosarcoma
or endometrial stromal sarcoma after treatment, FDG-PET/CT had a sen-
sitivity of 85.7% and a speciﬁcity of 100%, for detecting recurrence,
which was higher than that of conventional CT or MRI, albeit not statisti-
cally signiﬁcant [61]. FDG-PET/CT had an extremely high sensitivity of
100% and speciﬁcity of 100% for the detection of recurrent uterine
leiomyosarcoma in a small retrospective study [62]. Murakami et al. ad-
vocated that application of FDG-PET imaging for the early detection of re-
current sites was useful in the decision of treatment strategy for patients
with recurrent uterine sarcoma [63].
In detecting recurrent ovarian cancer, FDG-PET/CT had a sensitivity
of 85–97% and a speciﬁcity of 90–100% andwas higher than those of ul-
trasonography and CT [64], although negative predictive value is low
(42.9%) because of the high rate of false-negative ﬁndings for micro or
cystic lesions [65]. FDG-PET/CT modiﬁed the diagnostic or treatment
plan, by leading to the use of previously unplanned therapeutic proce-
dures in 57.9% of patients and the avoidance of previously planned diag-
nostic procedures in 42.1% of patients [66].
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PET/MR
The recently introduced hybrid PET/MRmight improve the diagnos-
tic performance of PET/CT, based on themajor strengths of MRI over CT,
including superior soft tissue contrast, multiplanar image acquisition
and functional imaging capability through specialized techniques.
Moreover, the absence of radiation usingMRmight be particularly ben-
eﬁcial in pediatric, young adult, or pregnant patients [8]. Initial results
(n = 19) in cervical cancer from hybrid PET/MR including Grueneisen
et al. revealed a signiﬁcant inverse correlation between SUVmax and
ADCmin of primary tumors (R=−0.342, p b 0.05) and associated pri-
mary LN metastases (R = −0.692, p b 0.001), measured in a hybrid
PET/MR system, whereas recurrent cervical cancer lesions did not
show a signiﬁcant correlation [67]. Hybrid PET/MR has also been
applied for radiation treatment planning in cervical cancer patients
but the results are controversial. Zhang et al. reported that tumor
volume discrepancies were observed between MR-GTV (manually T2-
weighted) and PET-GTV (auto-contoured by 40% SUV threshold) [68],
but a strong volume concordance between FDG-PET, and T2-weighted
and DWI was reported by Sun et al. [69]. Cost-effectiveness analysis
should be used as an end point in researches using new PET and MRI
technologies.
PET texture analysis
Texture analysis is an image process technique analyzing a set of
quantiﬁed metrics to represent the spatial arrangement of intensities in
a volume of interest on PET. Coarseness, contrast and heterogeneity are
frequently encountered metrics [70]. Although there is currently no evi-
dence of connection between image texture and tumor heterogeneity
at the cellular level, many researchers have tried texture analysis tech-
niques on functional PET or structural CT andMR images to ﬁnd potential
parameters for prognosis and treatment response, as alternatives to tradi-
tional parameters such as tumor volume and SUV. Yang et al. had
conducted a pilot study with 20 cervical cancer patients treated with
combined chemoradiation and suggested some texture parameters may
be better than SUV in predicting treatment outcome during the early
phase of treatment [71]. However, by ﬁnding a few potential ones from
a pool of numerous parameters with mathematical variation in a limited
set of patients, further prospective, large-scale studies have to be per-
formedwith the exact same parameters to validate their true utility. Tex-
ture analysis on functional and structuralmedical images is a complicated
ﬁeld with potentiality and with many questions to be clariﬁed [72].
Dynamic nuclear polarization (DNP)
Dynamic nuclear polarization (DNP) is a novel imaging technique
which uses specialized instrumentation to provide signal enhance-
ments of over 10,000-folds of magnitude for stable isotope carbon-13
(13C) enriched compounds [73]. Hyperpolarized [1-13C]pyruvate has
been used to study the real-time ﬂux of pyruvate to lactate non-
invasively following anticancer therapies in xenograft models. In addi-
tion to pyruvate, hyperpolarized H13CO3− has been demonstrated to
measure extracellular pH in lymphoma xenograft and [1,4-13C2]fuma-
rate showed the potential as an indicator of necrotic cell death [73].
The ﬁrst clinical trial of DNP-MRS has recently demonstrated the use
of hyperpolarized [1-13C]pyruvate to examine prostate cancer metabo-
lism in human [74], and paves the way to rapid translation of this excit-
ing technology to clinical research and perhaps clinical practice.
Chemical exchange saturation transfer (CEST) imaging
Chemical exchange saturation transfer (CEST) imaging is an emerg-
ing MRI approach in which exogenous or endogenous compoundscontaining either exchangeable protons or exchangeable molecules
are selectively saturated and after transfer of this saturation, detected
indirectly through the water signal with enhanced sensitivity [75].
By measuring the uptake of unlabeled glucose to be measured through
the chemical exchange of protons between hydroxyl groups and water,
Walker-Samuel et al. demonstrated that CEST was sensitive to tumor
glucose accumulation in colorectal tumor models and could distinguish
tumor types and potentially assessing response to therapy in the clinic
[76]. CEST using amide proton transfer imaging added to a standard
MR at 3T has been reported to have signiﬁcantly increased signal inten-
sity in brain tumor of 12 patients [77], yet there is no boundary to apply
this technique in the ﬁeld of gynecologic oncology.
Conclusions
In summary,molecular imaging (mainly PET andMRI) has played im-
portant roles in gynecologic oncology, for tumor detection, primary stag-
ing, treatment planning, prediction of prognosis, as well as response
evaluation, surveillance, and the management of recurrence. Emerging
imaging technologieswill continuously improve our practice. Such devel-
opment will aid decision-making in personalized medicine and precisely
guide radiation treatment plan or real-time surgical interventions, which
will directly impact on patient survival. No single imaging tool will uni-
versally apply in different tumor types. Prospective studies with deﬁned
endpoints are necessary to evaluate the roles of these emerging tools in
management of gynecologic malignancies.
Conﬂicts of interest statement
None declared.
Acknowledgments
Supported by research grant from Chang Gung Medical Foundation
(OMRPG3B0041) and the Department of Health and Welfare, Taiwan
(DOHW103-TDU-B-212-113003).
References
[1] Mankoff DA, Pryma DA, Clark AS. Molecular imaging biomarkers for oncology clini-
cal trials. J Nucl Med 2014;55(4):525–8.
[2] Shankar LK. The clinical evaluation of novel imaging methods for cancer manage-
ment. Nat Rev Clin Oncol 2012;9(12):738–44.
[3] Koh DM, Collins DJ. Diffusion-weightedMRI in the body: applications and challenges
in oncology. Am J Roentgenol 2007;188(6):1622–35.
[4] Hylton N. Dynamic contrast-enhanced magnetic resonance imaging as an imaging
biomarker. J Clin Oncol 2006;24(20):3293–8.
[5] Glunde K, Bhujwalla ZM. Metabolic tumor imaging using magnetic resonance spec-
troscopy. Semin Oncol 2011;38(1):26–41.
[6] Lai CH, Yen TC, Chang TC. Positron emission tomography imaging for gynecologic
malignancy. Curr Opin Obstet Gynecol 2007;19(1):37–41.
[7] Orlhac F, Soussan M, Maisonobe JA, Garcia CA, Vanderlinden B, Buvat I. Tumor tex-
ture analysis in 18F-FDG PET: relationships between texture parameters, histogram
indices, standardized uptake values, metabolic volumes, and total lesion glycolysis.
J Nucl Med 2014;55(3):414–22.
[8] Torigian DA, Zaidi H, Kwee TC, Saboury B, Udupa JK, Cho ZH, et al. PET/MR imaging:
technical aspects and potential clinical applications. Radiology 2013;267(1):26–44.
[9] Risum S, Hogdall C, Loft A, Berthelsen AK, Hogdall E, Nedergaard L, et al. The diag-
nostic value of PET/CT for primary ovarian cancer—a prospective study. Gynecol
Oncol 2007;105(1):145–9.
[10] Esseridou A, Di Leo G, Sconﬁenza LM, Caldiera V, Raspagliesi F, Grijuela B, et al.
In vivo detection of choline in ovarian tumors using 3D magnetic resonance spec-
troscopy. Invest Radiol 2011;46(6):377–82.
[11] Tanaka YO, Nishida M, Tsunoda H, Okamoto Y, Yoshikawa H. Smooth muscle
tumors of uncertain malignant potential and leiomyosarcomas of the uterus: MR
ﬁndings. J Magn Reson Imaging 2004;20(6):998–1007.
[12] Sato K, Yuasa N, Fujita M, Fukushima Y. Clinical application of diffusion-weighted
imaging for preoperative differentiation between uterine leiomyoma and
leiomyosarcoma. Am J Obstet Gynecol 2014;210(4) [368 e1-8].
[13] Yamane T, Takaoka A, KitaM, Imai Y, SendaM. 18F-FLT PET performs better than 18F-
FDG PET in differentiatingmalignant uterine corpus tumors frombenign leiomyoma.
Ann Nucl Med 2012;26(6):478–84.
[14] Lai CH, Yen TC, Ng KK. Molecular imaging in the management of cervical cancer.
J Formos Med Assoc 2012;111(8):412–20.
161C.-H. Lai et al. / Gynecologic Oncology 135 (2014) 156–162[15] Lakhman Y, Akin O, Park KJ, Sarasohn DM, Zheng J, Goldman DA, et al. Stage IB1 cer-
vical cancer: role of preoperative MR imaging in selection of patients for fertility-
sparing radical trachelectomy. Radiology 2013;269(1):149–58.
[16] Mitchell DG, Snyder B, Coakley F, Reinhold C, Thomas G, Amendola M, et al. Early in-
vasive cervical cancer: tumor delineation bymagnetic resonance imaging, computed
tomography, and clinical examination, veriﬁed by pathologic results, in the ACRIN
6651/GOG 183 Intergroup Study. J Clin Oncol 2006;24(36):5687–94.
[17] Hricak H, Gatsonis C, Chi DS, Amendola MA, Brandt K, Schwartz LH, et al. Role of
imaging in pretreatment evaluation of early invasive cervical cancer: results of
the intergroup study American College of Radiology Imaging Network 6651-
Gynecologic Oncology Group 183. J Clin Oncol 2005;23(36):9329–37.
[18] Epstein E, Testa A, Gaurilcikas A, Di Legge A, Ameye L, Atstupenaite V, et al. Early-
stage cervical cancer: tumor delineation by magnetic resonance imaging and ultra-
sound — a European multicenter trial. Gynecol Oncol 2013;128(3):449–53.
[19] Mitchell DG, Snyder B, Coakley F, Reinhold C, Thomas G, Amendola MA, et al. Early
invasive cervical cancer: MRI and CT predictors of lymphatic metastases in the
ACRIN 6651/GOG 183 intergroup study. Gynecol Oncol 2009;112(1):95–103.
[20] Lin G, Ho KC, Wang JJ, Ng KK, Wai YY, Chen YT, et al. Detection of lymph node me-
tastasis in cervical and uterine cancers by diffusion-weighted magnetic resonance
imaging at 3T. J Magn Reson Imaging 2008;28(1):128–35.
[21] Chou HH, Chang TC, Yen TC, Ng KK, Hsueh S, Ma SY, et al. Low value of [18F]-ﬂuoro-
2-deoxy-D-glucose positron emission tomography in primary staging of early-stage
cervical cancer before radical hysterectomy. J Clin Oncol 2006;24(1):123–8.
[22] Kitajima K, Yamasaki E, Kaji Y, Murakami K, Sugimura K. Comparison of DWI and
PET/CT in evaluation of lymph node metastasis in uterine cancer. World J Radiol
2012;4(5):207–14.
[23] Kim SK, Choi HJ, Park SY, Lee HY, Seo SS, Yoo CW, et al. Additional value of MR/PET
fusion compared with PET/CT in the detection of lymph node metastases in cervical
cancer patients. Eur J Cancer 2009;45(12):2103–9.
[24] Lai CH, Yen TC. When and how often should PET scans be performed in themanage-
ment of cervical cancer? Expert Rev Anticancer Ther 2010;10(7):983–6.
[25] Ramirez PT, Jhingran A, Macapinlac HA, Euscher ED, Munsell MF, Coleman RL, et al.
Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced
cervical cancer: a prospective correlation of surgical ﬁndings with positron emission
tomography/computed tomography ﬁndings. Cancer 2011;117(9):1928–34.
[26] Leblanc E, Gauthier H, Querleu D, Ferron G, Zerdoud S, Morice P, et al. Accuracy of
18-ﬂuoro-2-deoxy-D-glucose positron emission tomography in the pretherapeutic
detection of occult para-aortic node involvement in patients with a locally advanced
cervical carcinoma. Ann Surg Oncol 2011;18(8):2302–9.
[27] Chou HH, Chang HP, Lai CH, Ng KK, Hsueh S, Wu TI, et al. (18)F-FDG PET in stage IB/
IIB cervical adenocarcinoma/adenosquamous carcinoma. Eur J Nucl Med Mol Imag-
ing 2010;37(4):728–35.
[28] Tsai CS, Lai CH, Chang TC, Yen TC, Ng KK, Hsueh S, et al. A prospective randomized
trial to study the impact of pretreatment FDG-PET for cervical cancer patients with
MRI-detected positive pelvic but negative para-aortic lymphadenopathy. Int J Radiat
Oncol 2010;76(2):477–84.
[29] Loft A, Berthelsen AK, Roed H, Ottosen C, Lundvall L, Knudsen J, et al. The diagnostic
value of PET/CT scanning in patients with cervical cancer: a prospective study.
Gynecol Oncol 2007;106(1):29–34.
[30] Liu FY, Yen TC, Chen MY, Lai CH, Chang TC, Chou HH, et al. Detection of hematoge-
nous bone metastasis in cervical cancer: 18F-ﬂuorodeoxyglucose-positron emission
tomography versus computed tomography andmagnetic resonance imaging. Cancer
2009;115(23):5470–80.
[31] Onal C, Oymak E, Findikcioglu A, Reyhan M. Isolated mediastinal lymph node false
positivity of [18F]-ﬂuorodeoxyglucose-positron emission tomography/computed to-
mography in patients with cervical cancer. Int J Gynecol Cancer 2013;23(2):337–42.
[32] Antonsen SL, Jensen LN, Loft A, Berthelsen AK, Costa J, Tabor A, et al. MRI, PET/CT and
ultrasound in the preoperative staging of endometrial cancer — a multicenter pro-
spective comparative study. Gynecol Oncol 2013;128(2):300–8.
[33] Lin G, Ng KK, Chang CJ, Wang JJ, Ho KC, Yen TC, et al. Myometrial invasion in endo-
metrial cancer: diagnostic accuracy of diffusion-weighted 3.0-T MR imaging–initial
experience. Radiology 2009;250(3):784–92.
[34] Horowitz NS, Dehdashti F, Herzog TJ, Rader JS, Powell MA, Gibb RK, et al. Prospective
evaluation of FDG-PET for detecting pelvic and para-aortic lymph nodemetastasis in
uterine corpus cancer. Gynecol Oncol 2004;95(3):546–51.
[35] Suzuki R, Miyagi E, Takahashi N, Sukegawa A, Suzuki A, Koike I, et al. Validity of pos-
itron emission tomography using ﬂuoro-2-deoxyglucose for the preoperative evalu-
ation of endometrial cancer. Int J Gynecol Cancer 2007;17(4):890–6.
[36] Ho KC, Lai CH, Wu TI, Ng KK, Yen TC, Lin G, et al. 18F-ﬂuorodeoxyglucose positron
emission tomography in uterine carcinosarcoma. Eur J Nucl Med Mol Imaging
2008;35(3):484–92.
[37] Hynninen J, AuranenA, CarpenO,Dean K, SeppanenM,Kemppainen J, et al. FDG PET/
CT in staging of advanced epithelial ovarian cancer: frequency of supradiaphragmatic
lymph node metastasis challenges the traditional pattern of disease spread. Gynecol
Oncol 2012;126(1):64–8.
[38] Yuan Y, Gu ZX, Tao XF, Liu SY. Computer tomography, magnetic resonance imaging,
and positron emission tomography or positron emission tomography/computer to-
mography for detection of metastatic lymph nodes in patients with ovarian cancer:
a meta-analysis. Eur J Radiol 2012;81(5):1002–6.
[39] Michielsen K, Vergote I, Op de Beeck K, Amant F, Leunen K,Moerman P, et al. Whole-
body MRI with diffusion-weighted sequence for staging of patients with suspected
ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT.
Eur Radiol 2014;24(4):889–901.
[40] Kataoka MY, Sala E, Baldwin P, Reinhold C, Farhadi A, Hudolin T, et al. The accuracy
of magnetic resonance imaging in staging of vulvar cancer: a retrospective multi-
centre study. Gynecol Oncol 2010;117(1):82–7.[41] Cohn DE, Dehdashti F, Gibb RK,Mutch DG, Rader JS, Siegel BA, et al. Prospective eval-
uation of positron emission tomography for the detection of groin node metastases
from vulvar cancer. Gynecol Oncol 2002;85(1):179–84.
[42] Kidd EA, Grigsby PW. Intratumoral metabolic heterogeneity of cervical cancer. Clin
Cancer Res 2008;14(16):5236–41.
[43] Crivellaro C, Signorelli M, Guerra L, De Ponti E, Buda A, Dolci C, et al. 18F-FDG PET/CT
can predict nodal metastases but not recurrence in early stage uterine cervical can-
cer. Gynecol Oncol 2012;127(1):131–5.
[44] Yen TC, See LC, Lai CH, Tsai CS, ChaoA,HsuehS, et al. Standardizeduptake value in para-
aortic lymph nodes is a signiﬁcant prognostic factor in patients with primary advanced
squamous cervical cancer. Eur J Nucl Med Mol Imaging 2008;35(3):493–501.
[45] Ho KC, Wang CC, Qiu JT, Lai CH, Hong JH, Huang YT, et al. Identiﬁcation of prognostic
factors in patients with cervical cancer and supraclavicular lymph node recurrence.
Gynecol Oncol 2011;123(2):253–6.
[46] Antonsen SL, Loft A, Fisker R, Nielsen AL, Andersen ES, Hogdall E, et al. SUVmax of
18FDG PET/CT as a predictor of high-risk endometrial cancer patients. Gynecol
Oncol 2013;129(2):298–303.
[47] Nakamura K, Joja I, Fukushima C, Haruma T, Hayashi C, Kusumoto T, et al. The
preoperative SUVmax is superior to ADCmin of the primary tumour as a predictor
of disease recurrence and survival in patients with endometrial cancer. Eur J Nucl
Med Mol Imaging 2013;40(1):52–60.
[48] Liu FY, Chao A, Lai CH, ChouHH, Yen TC.Metabolic tumor volume by 18F-FDG PET/CT is
prognostic for stage IVB endometrial carcinoma. Gynecol Oncol 2012;125(3):566–71.
[49] NCCN Clinical Practice Guidelines in Oncology: Uterine Cancers. National Compre-
hensive Cancer Network Web site. http://www.nccn.org/professionals/physician_
gls/pdf/uterine.pdf. [Accessed July 03, 2014].
[50] deSouza NM, Soutter WP, Rustin G, Mahon MM, Jones B, Dina R, et al. Use of neoad-
juvant chemotherapy prior to radical hysterectomy in cervical cancer: monitoring
tumour shrinkage and molecular proﬁle on magnetic resonance and assessment of
3-year outcome. Br J Cancer 2004;90(12):2326–31.
[51] Harry VN, Semple SI, Gilbert FJ, Parkin DE. Diffusion-weighted magnetic resonance
imaging in the early detection of response to chemoradiation in cervical cancer.
Gynecol Oncol 2008;111(2):213–20.
[52] Chang TC, Law KS, Hong JH, Lai CH, Ng KK, Hsueh S, et al. Positron emission tomog-
raphy for unexplained elevation of serum squamous cell carcinoma antigen levels
during follow-up for patients with cervical malignancies: a phase II study. Cancer
2004;101(1):164–71.
[53] Chung HH, Kim JW, Kang KW, Park NH, Song YS, Chung JK, et al. Predictive role of
post-treatment [18F]FDG PET/CT in patients with uterine cervical cancer. Eur J Radiol
2012;81(8):e817–22.
[54] Yen TC, See LC, Chang TC, Huang KG, Ng KK, Tang SG, et al. Deﬁning the priority of
using 18F-FDG PET for recurrent cervical cancer. J Nucl Med 2004;45(10):1632–9.
[55] Lai CH, Huang KG, See LC, Yen TC, Tsai CS, Chang TC, et al. Restaging of recurrent cer-
vical carcinoma with dual-phase [18F]ﬂuoro-2-deoxy-D-glucose positron emission
tomography. Cancer 2004;100(3):544–52.
[56] Yen TC, Lai CH, Ma SY, Huang KG, Huang HJ, Hong JH, et al. Comparative beneﬁts and
limitations of 18F-FDG PET and CT-MRI in documented or suspected recurrent cervi-
cal cancer. Eur J Nucl Med Mol Imaging 2006;33(12):1399–407.
[57] Lin CT, Yen TC, Chang TC, Ng KK, Tsai CS, Ho KC, et al. Role of [18F]ﬂuoro-2-deoxy-D-
glucose positron emission tomography in re-recurrent cervical cancer. Int J Gynecol
Cancer 2006;16(6):1994–2003.
[58] Park JY, Kim EN, Kim DY, Kim JH, Kim YM, Kim YT, et al. Clinical impact of positron
emission tomography or positron emission tomography/computed tomography in
the posttherapy surveillance of endometrial carcinoma: evaluation of 88 patients.
Int J Gynecol Cancer 2008;18(6):1332–8.
[59] Chao A, Chang TC, Ng KK, Hsueh S, Huang HJ, Chou HH, et al. 18F-FDG PET in the
management of endometrial cancer. Eur J NuclMedMol Imaging 2006;33(1):36–44.
[60] Sironi S, Picchio M, Landoni C, Galimberti S, Signorelli M, Bettinardi V, et al. Post-
therapy surveillance of patients with uterine cancers: value of integrated FDG PET/
CT in the detection of recurrence. Eur J Nucl Med Mol Imaging 2007;34(4):472–9.
[61] Sharma P, Kumar R, Singh H, Jeph S, Sharma JB, Jain SK, et al. Role of FDG PET-CT in
detecting recurrence in patients with uterine sarcoma: comparison with conven-
tional imaging. Nucl Med Commun 2012;33(2):185–90.
[62] Kao YH, Saad U, Tan AE, Magsombol BM, Padhy AK. Fluorine-18-ﬂuorodeoxyglucose
PET/CT for the evaluation of suspected recurrent uterine leiomyosarcomas. Acta
Radiol 2011;52(4):463–6.
[63] Murakami M, Tsukada H, Shida M, Watanabe M, Maeda H, Koido S, et al. Whole-
body positron emission tomography with F-18 ﬂuorodeoxyglucose for the detection
of recurrence in uterine sarcomas. Int J Gynecol Cancer 2006;16(2):854–60.
[64] Risum S, Hogdall C, Markova E, Berthelsen AK, Loft A, Jensen F, et al. Inﬂuence of 2-
(18F) ﬂuoro-2-deoxy-D-glucose positron emission tomography/computed tomogra-
phy on recurrent ovarian cancer diagnosis and on selection of patients for secondary
cytoreductive surgery. Int J Gynecol Cancer 2009;19(4):600–4.
[65] Takekuma M, Maeda M, Ozawa T, Yasumi K, Torizuka T. Positron emission tomogra-
phy with 18F-ﬂuoro-2-deoxyglucose for the detection of recurrent ovarian cancer.
Int J Clin Oncol 2005;10(3):177–81.
[66] Chung HH, KangWJ, Kim JW, Park NH, Song YS, Chung JK, et al. Role of [18F]FDG PET/
CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical
or histological ﬁndings. Eur J Nucl Med Mol Imaging 2007;34(4):480–6.
[67] Grueneisen J, Beiderwellen K, Heusch P, Buderath P, Aktas B, Gratz M, et al. Correla-
tion of standardized uptake value and apparent diffusion coefﬁcient in integrated
whole-body PET/MRI of primary and recurrent cervical cancer. PLoS One 2014;
9(5):e96751.
[68] Zhang S, Xin J, Guo Q, Ma J, Ma Q, Sun H. Comparison of tumor volume between
PET and MRI in cervical cancer with hybrid PET/MR. Int J Gynecol Cancer 2014;
24(4):744–50.
162 C.-H. Lai et al. / Gynecologic Oncology 135 (2014) 156–162[69] Sun H, Xin J, Zhang S, Guo Q, Lu Y, Zhai W, et al. Anatomical and functional volume
concordance between FDG PET, and T2 and diffusion-weighted MRI for cervical
cancer: a hybrid PET/MR study. Eur J Nucl Med Mol Imaging 2014;41(5):898–905.
[70] Chicklore S, Goh V, Siddique M, Roy A, Marsden PK, Cook GJ. Quantifying tumour
heterogeneity in 18F-FDG PET/CT imaging by texture analysis. Eur J Nucl Med Mol
Imaging 2013;40(1):133–40.
[71] Yang F, Thomas MA, Dehdashti F, Grigsby PW. Temporal analysis of intratumoral
metabolic heterogeneity characterized by textural features in cervical cancer. Eur J
Nucl Med Mol Imaging 2013;40(5):716–27.
[72] Brooks FJ. On some misconceptions about tumor heterogeneity quantiﬁcation. Eur J
Nucl Med Mol Imaging 2013;40(8):1292–4.
[73] Gallagher FA, Kettunen MI, Hu DE, Jensen PR, Zandt RI, Karlsson M, et al. Production
of hyperpolarized [1,4-13C2]malate from [1,4-13C2]fumarate is a marker of cellnecrosis and treatment response in tumors. Proc Natl Acad Sci U S A 2009;
106(47):19801–6.
[74] Nelson SJ, Kurhanewicz J, Vigneron DB, Larson PE, Harzstark AL, Ferrone M, et al.
Metabolic imaging of patients with prostate cancer using hyperpolarized [1-13C]py-
ruvate. Sci Transl Med 2013;5(198):98ra08.
[75] van Zijl PC, Yadav NN. Chemical exchange saturation transfer (CEST): what is in a
name and what isn't? Magn Reson Med 2011;65(4):927–48.
[76] Walker-Samuel S, Ramasawmy R, Torrealdea F, Rega M, Rajkumar V, Johnson SP,
et al. In vivo imaging of glucose uptake and metabolism in tumors. Nat Med 2013;
19(8):1067–72.
[77] Wen Z, Hu S, Huang F, Wang X, Guo L, Quan X, et al. MR imaging of high-grade brain
tumors using endogenous protein and peptide-based contrast. Neuroimage 2010;
51(2):616–22.
